MMRV

BIOLOGICAL4 trials

Sponsors

GlaxoSmithKline, Novartis Vaccines, CHU de Quebec-Universite Laval

Conditions

MeaslesMeningococcal InfectionsMumpsRubellaVaricella

Phase 3

Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine

CompletedNCT00406211

GlaxoSmithKlineMeasles, Mumps, Rubella +1

Start: 2004-07-31End: 2004-12-31Updated: 2016-09-15

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

CompletedNCT00626327

Novartis VaccinesMeningococcal Infections

Start: 2008-02-29End: 2010-10-31Updated: 2013-04-19

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

Not yet recruitingNCT07406360

GlaxoSmithKlineMeasles

Start: 2026-04-13End: 2028-06-22Target: 1209Updated: 2026-02-12

Unknown Phase

Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization

CompletedNCT02712177

CHU de Quebec-Universite LavalMeningococcal Infections

Start: 2008-08-31End: 2019-04-30Updated: 2019-08-07

Related Papers

Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials

BMJ Open2019-05-1720 citations

Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

2011-09-2114 citations